MTFB News and Press, Motif Bio plc From 07/15/19

NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has submitted a meeting request and package to the U.S. Food & Drug Administration (FDA) related...

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting hel...

The following slide deck was published by Motif Bio plc in conjunction with this Read more ...

Gainers:  Stewardship Financial (NASDAQ: SSFN ) +73% . Beyond Meat (NASDAQ: BYND ) +36% . La Jolla Pharmaceutical (NASDAQ: LJPC ) +25% . ReWalk Robotics (NASDAQ: RWLK ) +26% . Neptune Wellness Solutions (NASDAQ: NEPT ) +21% . Zoom Video Communications (NASDAQ: ZM ) +21% . Horizo...

The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for drug-resistant infections WASHINGTON , June 7, 2019 /PRNewswire/ -- The Antimi...

Charles & Colvard (NASDAQ: CTHR )  -19%  on Q4 and FY guidance  and equity offering . More news on: Charles & Colvard, Ltd., Motif Bio plc, Domo, Inc., Stocks on the move, Read more ...

Gainers:  La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...

Motif Bio (NASDAQ: MTFB )  -48%  on announcing path forward for Iclaprim. More news on: Motif Bio plc, At Home Group Inc., Cloudera, Inc., Stocks on the move, Read more ...

Motif Bio (NASDAQ: MTFB ) has received the official minutes of the Type A meeting held with FDA on May 3, to discuss the points raised in the Complete Response Letter (CRL) related to the NDA for iclaprim, for the treatment of acute bacterial skin and skin structure infections. More...

NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received the official minutes of the Type A meeting the Company held with the U.S. Food...